Literature DB >> 18758989

Biochemical and molecular diagnosis of erythropoietic protoporphyria in an Ashkenazi Jewish family.

X Schneider-Yin1, R Mamet, E I Minder, N Schoenfeld.   

Abstract

Erythropoietic protoporphyria (EPP) is a rare hereditary disorder due to a partial deficiency of ferrochelatase (FECH). The genotype of EPP patients features a mutation on one allele of the FECH gene and a common hypomorphic FECH IVS3-48c on the other allele (M/c). The resulting enzyme activity in patients is ∼35% of that in normal individuals. Ferrochelatase deficiency results in the accumulation of protoporphyrin in the skin, which is responsible for the clinical symptom of cutaneous photosensitivity in patients. In this study, we report the identification of a novel FECH mutation delT23 in an 11-member EPP family of Jewish origin. Two EPP siblings shared an identical genotype of delT23/IVS3-48c (M/c). They were both photosensitive and showed highly increased erythrocyte protoporphyrin. The genotype of the patients' mother, who did not present with any EPP clinical symptoms, was delT23/IVS3-48t (M/t). The patients' father, an offspring of consanguineous parents, was homozygous IVS3-48 c/c. He exhibited a mild photosensitivity, and an increase of 4-fold in erythrocyte protoporphyrin. His FECH mRNA amount was 71% of that of genotype t/t. It is the first reported case of an individual with c/c genotype who exhibits both biochemical and clinical indications of EPP. These results suggest that IVS3-48c is a functional variant of ferrochelatase. The clinical symptoms and biochemical abnormalities in the patients' father could be the result of an interaction between genetic and environmental factors. In addition, the frequency of IVS3-48c in the Ashkenazi Jewish population was estimated at 8%, which is similar to that in the European populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758989     DOI: 10.1007/s10545-008-0924-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  14 in total

1.  Novel ferrochelatase mutations in Japanese patients with erythropoietic protoporphyria: high frequency of the splice site modulator IVS3-48C polymorphism in the Japanese population.

Authors:  Hajime Nakano; Aoi Nakano; Yuka Toyomaki; Shigeki Ohashi; Ken Harada; Ryuta Moritsugu; Hitoshi Takeda; Akira Kawada; Yoshihiko Mitsuhashi; Katsumi Hanada
Journal:  J Invest Dermatol       Date:  2006-06-22       Impact factor: 8.551

2.  A metric map of humans: 23,500 loci in 850 bands.

Authors:  A Collins; J Frezal; J Teague; N E Morton
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

3.  Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life.

Authors:  S A Holme; A V Anstey; A Y Finlay; G H Elder; M N Badminton
Journal:  Br J Dermatol       Date:  2006-09       Impact factor: 9.302

4.  A micromethod for free erythrocyte porphyrins: the FEP test.

Authors:  S Piomelli
Journal:  J Lab Clin Med       Date:  1973-06

5.  Heterogeneity of mutations in the ferrochelatase gene in Italian patients with erythropoietic protoporphyria.

Authors:  Caterina Aurizi; Xiaoye Schneider-Yin; Fiammetta Sorge; Annelisa Macrì; Elisabeth I Minder; Gianfranco Biolcati
Journal:  Mol Genet Metab       Date:  2006-12-29       Impact factor: 4.797

6.  Detection of latent variegate porphyria by fluorescence emission spectroscopy of plasma.

Authors:  C Long; S J Smyth; J Woolf; G M Murphy; A Y Finlay; R G Newcombe; G H Elder
Journal:  Br J Dermatol       Date:  1993-07       Impact factor: 9.302

7.  Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias.

Authors:  C K Lim; T J Peters
Journal:  Clin Chim Acta       Date:  1984-05-16       Impact factor: 3.786

8.  Clinical porphyrin analyses: indications and interpretations.

Authors:  T K With
Journal:  Scand J Clin Lab Invest       Date:  1978-10       Impact factor: 1.713

9.  Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria.

Authors:  Laurent Gouya; Caroline Martin-Schmitt; Anne-Marie Robreau; Frederic Austerlitz; Vasco Da Silva; Patrick Brun; Sylvie Simonin; Said Lyoumi; Bernard Grandchamp; Carole Beaumont; Herve Puy; Jean-Charles Deybach
Journal:  Am J Hum Genet       Date:  2005-11-15       Impact factor: 11.025

10.  Identification of a ferrochelatase mutation in a Chinese family with erythropoietic protoporphyria.

Authors:  Xiao-Fei Kong; Jing Ye; De-Yong Gao; Qi-Ming Gong; Dong-Hua Zhang; Zhi-Meng Lu; Yi-Ming Lu; Xin-Xin Zhang
Journal:  J Hepatol       Date:  2007-11-26       Impact factor: 25.083

View more
  3 in total

1.  Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice.

Authors:  Jasmin Barman-Aksözen; Paulina C Wiek; Vijay B Bansode; Frank Koentgen; Judith Trüb; Pawel Pelczar; Paolo Cinelli; Xiaoye Schneider-Yin; Daniel Schümperli; Elisabeth I Minder
Journal:  Dis Model Mech       Date:  2017-01-12       Impact factor: 5.758

Review 2.  Erythropoietic protoporphyria.

Authors:  Mario Lecha; Hervé Puy; Jean-Charles Deybach
Journal:  Orphanet J Rare Dis       Date:  2009-09-10       Impact factor: 4.123

3.  Porphyria: What Is It and Who Should Be Evaluated?

Authors:  Yonatan Edel; Rivka Mamet
Journal:  Rambam Maimonides Med J       Date:  2018-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.